• +1-646-491-9876
    • +91-20-67278686

    Search

    Galectin 3 Pipeline Review H1 2017

    Galectin 3 Pipeline Review H1 2017

    • Report Code ID: RW0001851084
    • Category Life Sciences
    • No. of Pages 77
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H1 2017

    Summary

    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Galectin-3 is a protein encoded by the LGALS3 gene. It mediates with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. It acts as a pre-mRNA splicing factor. It is involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells.

    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) pipeline Target constitutes close to 18 molecules. Out of which approximately 18 molecules are developed by Companies.The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 12 and 4 respectively. Report covers products from therapy areas Oncology, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Respiratory, Dermatology, Musculoskeletal Disorders, Ophthalmology, Undisclosed, Immunology and Metabolic Disorders which include indications Kidney Fibrosis, Liver Fibrosis, Myocardial Fibrosis, Atopic Dermatitis, Fibrosis, Liver Cirrhosis, Non-Alcoholic Steatohepatitis (NASH) , Portal Hypertension, Prostate Cancer, Pulmonary Arterial Hypertension, Pulmonary Fibrosis, Unspecified, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Breast Cancer, Colorectal Cancer, Corneal Neovascularization, Diabetic Nephropathy, Head And Neck Cancer Squamous Cell Carcinoma, Idiopathic Pulmonary Fibrosis, Keratoconjunctivitis sicca (Dry Eye) , Metastatic Breast Cancer, Metastatic Melanoma, Multiple Myeloma (Kahler Disease) , Non-Small Cell Lung Cancer, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris) and Sarcomas.

    The latest report Galectin 3 - Pipeline Review, H1 2017, outlays comprehensive information on the Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3)
    - The report reviews Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Overview
    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Companies Involved in Therapeutics Development
    Angion Biomedica Corp
    Bristol-Myers Squibb Company
    Galectin Therapeutics Inc
    GlycoMimetics Inc
    iTeos Therapeutics SA
    MandalMed Inc
    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Drug Profiles
    ANG-4021 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    G-XXX - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gal-200 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GAL-300 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gal-400 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GMCT-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GRMD-02 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GRMD-03 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GRMD-04 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KTI - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit Galectin-3 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Protearin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Galectin-1, 3, 9 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TD-139 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TFD-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Dormant Products
    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Discontinued Products
    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Product Development Milestones
    Featured News & Press Releases
    Jun 13, 2017: Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial
    Jun 06, 2017: Autoimmune Disease Patent Granted to Galectin Therapeutics
    Apr 25, 2017: Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02
    Apr 18, 2017: Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress 2017
    Mar 14, 2017: GR-MD-02 Demonstrates Clinically Significant Effect in Patients with Severe and Refractory Atopic Dermatitis (Eczema)
    Mar 06, 2017: Galectin's GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis
    Feb 07, 2017: Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials
    Feb 01, 2017: Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial
    Nov 21, 2016: Galectin Therapeutics and CTI Announce Positive New Psoriasis and Atopic Dermatitis Clinical Data
    Nov 10, 2016: Galectin Therapeutics Announces Positive New Psoriasis and Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships for Therapy of Severe Skin Diseases
    Oct 07, 2016: Galectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic Steatohepatitis
    Sep 27, 2016: Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis
    Aug 25, 2016: Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial
    Aug 02, 2016: Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis
    Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Angion Biomedica Corp, H1 2017
    Pipeline by Bristol-Myers Squibb Company, H1 2017
    Pipeline by Galectin Therapeutics Inc, H1 2017
    Pipeline by GlycoMimetics Inc, H1 2017
    Pipeline by iTeos Therapeutics SA, H1 2017
    Pipeline by MandalMed Inc, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Angion Biomedica Corp
    Bristol-Myers Squibb Company
    Galectin Therapeutics Inc
    GlycoMimetics Inc
    iTeos Therapeutics SA
    MandalMed Inc

    Request for Sample

    Report Url https://www.reportsweb.com//galectin-3-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//galectin-3-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//galectin-3-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments